<DOC>
	<DOCNO>NCT01192984</DOCNO>
	<brief_summary>The purpose study evaluate efficacy KW-0761 intravenously administer eight time one-week interval patient CCR4-positive peripheral T/NK-cell lymphoma . The primary objective ass antitumor effect term best overall response , secondary objective assess antitumor effect term best response disease lesion , assess progression-free survival ass overall survival . The safety pharmacokinetic profile KW-0761 also evaluate .</brief_summary>
	<brief_title>Study KW-0761 Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<criteria>Subjects hematologically pathohistologically diagnosed peripheral T/NKcell lymphoma Subjects positive CCR4 Subjects receive one chemotherapy regimens Subjects relapse achieve complete response , uncertain complete response partial response last chemotherapy Subjects interval 4 week last day prior therapy schedule day first KW0761 treatment Subjects nodal lesion , extranodal lesion and/or cutaneous lesion Subjects performance status 0 2 Subjects negative HBs antigen report `` detect '' HBVDNA Subjects negative antiHCV antibody Subjects normal function major organ Subjects give write voluntary inform consent participate study Subjects underwent transplant therapy hematopoietic stemcell transplantation ( Subjects undergo autologous hematopoietic stemcell transplantation follow chemotherapy exclude ) Subjects know carrier HIV Subjects active multiple cancer Subjects history allergic reaction therapeutic antibody Subjects require continuous systemic treatment steroid Subjects require emergency radiotherapy treat symptom cause bulky mass enrollment may require radiotherapy start study Subjects pregnant , lactate childbearing potential , plan child</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>